Although patients with MDS and AML shared common gross structural aberrations and intragenic TP53 aberrations (Figure 1), there was substantial diversity in each patient's allelic state, response to front‐line therapy, HCT candidacy, and ultimately clinical outcomes. Here, TP53 is linked to acute myeloid leukemia.